A phase 2 study of abemaciclib plus pembrolizumab for patients with hormone receptor positive (HR+), HER2 negative (HER2-) metastatic breast cancer (MBC)

被引：0
|
作者：
Rugo, H.
Tolaney, S.
Dickler, M.
Kabos, P.
Ho, C-L
Wildiers, H.
Jerusalem, G.
Ales-Martinez, J. E.
Hossain, A.
Johnston, E.
Gianni, L.
机构：
[1] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA
[2] Dana Farber Canc Inst, Boston, MA 02115 USA
[3] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[4] Univ Colorado, Anschutz Med Campus, Aurora, CO USA
[5] Tri Serv Gen Hosp, Natl Def Med Ctr, Taipei, Taiwan
[6] Univ Ziekenhuis Leuven Gasthuisbert, Leuven, Belgium
[7] Univ Sart Tilman, Ctr Hospitalier, Liege, Belgium
[8] Hosp Nuestra Senora Sonsoles, Complejo Hospitalario Avila Oncol, Avila, Spain
[9] Eli Lilly & Co, Indianapolis, IN 46285 USA
[10] IRCCS Osped, Milan, Italy
来源：
CANCER RESEARCH | 2017年 / 77卷
关键词：
D O I：
10.1158/1538-7445.SABCS16-OT2-01-07
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
OT2-01-07
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Metastatic patterns and outcomes by HER2 and hormone receptor (HR) status in patients (pts) with metastatic breast cancer (mBC)
    Yuan, Qianyu
    Castellanos, Emily
    Fidyk, Erin
    Schwed, Karen
    Estevez, Melissa
    Nemeth, Sheila
    Linzmayer, Robin
    Cohen, Aaron B.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [32] "Real world" characteristics, treatment patterns and outcomes of patients with hormone receptor positive (HR plus ), human epidermal growth factor 2 negative (HER2-) metastatic breast cancer (MBC)
    Twelves, C.
    Cheeseman, S.
    Thompson, M.
    Riaz, M.
    Perren, T.
    Ahat-Donker, N.
    Sopwith, W.
    Myland, M.
    Lee, A.
    Turner, S.
    Hall, G.
    CANCER RESEARCH, 2019, 79 (04)
  • [33] A phase II study of abemaciclib in patients (pts) with brain metastases (BM) secondary to HR+, HER2-metastatic breast cancer (MBC).
    Anders, Carey K.
    Le Rhun, Emilie
    Bachelot, Thomas Denis
    Yardley, Denise A.
    Awada, Ahmad
    Conte, Pier Franco
    Kabos, Peter
    Bear, Melissa
    Yang, Zhengyu
    Chen, Yanyun
    Tolaney, Sara M.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [34] TATEN TRIAL (SOLTI-1716) Targeting non-Luminal disease by PAM50 with pembrolizumab plus paclitaxel in Hormone Receptor-positive/HER2-negative (HR+/HER2-) metastatic breast cancer (MBC): interim analysis
    Prat, Aleix
    Pascual, Tomas
    Munoz, Montserrat
    Hernando, Cristina
    Vazquez, Silvia
    Blanch, Salvador
    Alva, Manuel
    Oliveira, Mafalda
    Sanfeliu, Esther
    Villanueva, Lorea
    Braso-Maristany, Fara
    Chic, Nuria
    Ciruelos, Eva
    CANCER RESEARCH, 2023, 83 (05)
  • [35] Final overall survival (OS) analysis from the phase 3 TROPiCS-02 study of sacituzumab govitecan (SG) in patients (pts) with hormone receptor-positive/HER2-negative (HR+/HER2-) metastatic breast cancer (mBC)
    Tolaney, Sara M.
    Bardia, Aditya
    Marme, Frederik
    Cortes, Javier
    Schmid, Peter
    Loirat, Delphine
    Tredan, Olivier
    Ciruelos, Eva M.
    Dalenc, Florence
    Pardo, Patricia Gomez
    Jhaveri, Komal L.
    Delaney, Rosemary
    Valdez, Theresa
    Yoon, Oh Kyu
    Wang, Hao
    Verret, Wendy
    Rugo, Hope S.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [36] Final overall survival (OS) analysis from the phase 3 TROPiCS-02 study of sacituzumab govitecan (SG) in patients (pts) with hormone receptor-positive/HER2-negative (HR+/HER2-) metastatic breast cancer (mBC)
    Tesch, H.
    Tolaney, S.
    Bardia, A.
    Marme, F.
    Cortes, J.
    Schmid, P.
    Loirat, D.
    Tredan, O.
    Ciruelos, E.
    Dalenc, F.
    Pardo, Gomez P.
    Jhaveri, K.
    Delaney, R.
    Valdez, T.
    Yoon, O. K.
    Wang, H.
    Verret, W.
    Rugo, H.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 29 - 30
  • [37] First-line ribociclib plus letrozole for postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2-), advanced breast cancer (ABC)
    Hortobagyi, G. N.
    Stemmer, S. M.
    Burris, H. A.
    Yap, Y. S.
    Sonke, G. S.
    Paluch-Shimon, S.
    Campone, M.
    Blackwell, K.
    Andre, F.
    Winer, E. P.
    Janni, W.
    Verma, S.
    Conte, P.
    Arteaga, C. L.
    Cameron, D.
    Xuan, F.
    Souami, F.
    Miller, M.
    Germa, C.
    O'Shaughnessy, J.
    ANNALS OF ONCOLOGY, 2016, 27
  • [38] Ribociclib (RIB) plus endocrine therapy (ET) in Japanese women with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC)
    Masuda, N.
    Noguchi, S.
    Ishikawa, T.
    Aruga, T.
    Kim, S. J.
    Toyama, T.
    Saeki, T.
    Saito, M.
    Yamanaka, T.
    Watanabe, J.
    Nakamura, S.
    Takahashi, M.
    Inoue, K.
    Gounaris, I.
    Han, Y.
    Samant, T. S.
    Gazdoiu, M.
    Ito, Y.
    ANNALS OF ONCOLOGY, 2018, 29
  • [39] Bone-Induced HER2 Promotes Secondary Metastasis in HR+/HER2- Breast Cancer
    Alam, Rahat
    Reva, Anna
    Edwards, David G.
    Lege, Bree M.
    Munoz-Arcos, Laura S.
    Reduzzi, Carolina
    Singh, Swarnima
    Hao, Xiaoxin
    Wu, Yi-Hsuan
    Tian, Zeru
    Natalee, Laura M.
    Damle, Gargi
    Demircioglu, Deniz
    Wang, Yixian
    Wu, Ling
    Molteni, Elisabetta
    Hasson, Dan
    Lim, Bora
    Gugala, Zbigniew
    Chipuk, Jerry E.
    Lang, Julie E.
    Sparano, Joseph A.
    Cheng, Chonghui
    Cristofanilli, Massimo
    Xiao, Han
    Zhang, Xiang H. -F.
    Bado, Igor L.
    CANCER DISCOVERY, 2025, 15 (04) : 818 - 837
  • [40] Abemaciclib in HR+/HER2-metastatic breast cancer: A realworld experience
    Bottosso, M.
    Giarratano, T.
    Barbieri, C.
    Menichetti, A.
    Cumerlato, E.
    Miglietta, F.
    Genovesi, E.
    Amato, O.
    Dieci, M. V.
    Griguolo, G.
    Guarneri, V.
    ANNALS OF ONCOLOGY, 2021, 32 : S73 - S74
12345